Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Rivadeneira

Colon & Rectal Surgery Woodbury, NY Medical Doctor

NPI 1457370785 CMS profile 111647

321B Crossways Park Dr, Woodbury, NY 11797

Open in the dashboard

General payments

$271,311

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Rivadeneira of Woodbury, NY is reported in the CMS Open Payments database as having received $271,311 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64,296 23
2024 General $102,889 33
2023 General $49,217 35
2022 General $4,381 15
2021 General $15,771 22
2020 General $21,970 22
2019 General $12,786 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Rivadeneira
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to David Rivadeneira were reported at $64,296. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year David Rivadeneira Colon & Rectal Surgery median Middle half National median
2019 $12,786 $443 $125–$2,179 $163
2020 $21,970 $167 $53–$931 $114
2021 $15,771 $207 $72–$1,272 $132
2022 $4,381 $341 $111–$1,587 $149
2023 $49,217 $322 $115–$1,420 $160
2024 $102,889 $328 $112–$1,354 $164
2025 $64,296 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Evologics LLC $85,000 2 payments
  2. Dilon Technologies, Inc. $48,367 35 payments
  3. Stryker Corporation $39,516 2 payments
  4. Biom'Up France SAS $32,279 20 payments
  5. Integra LifeSciences Corporation $26,328 23 payments
  6. Guard Medical Inc. $17,055 16 payments
  7. Applied Medical Resources Corporation $11,059 9 payments
  8. Biom'Up SA $6,695 9 payments
  9. TEI Biosciences Inc $3,091 14 payments
  10. Intuitive Surgical, Inc. $244 2 payments
  11. Other $1,677 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $184,500 31 payments
  2. Acquisitions $39,475 1 payment
  3. Honoraria $15,000 7 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,000 11 payments
  5. Travel and Lodging $11,244 16 payments
  6. Food and Beverage $7,073 126 payments
  7. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. HEMOBLAST BELLOWS Hemostatic Agent $63,457 43 payments
  2. Integra $18,695 10 payments
  3. OMNIGRAFT $17,236 7 payments
  4. HemoBlast Bellows Hemostatic Agent $17,117 11 payments
  5. NPSEAL LARGE $16,917 15 payments
  6. Gelport Laparoscopic System $10,515 7 payments
  7. NPSEAL (5) $9,792 11 payments
  8. NPSEAL MEDIUM $9,792 11 payments
  9. FLOWABLE $7,000 3 payments
  10. INTEGRA WOUND MATRIX (IWM) $7,000 3 payments
  11. Other $32,193 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

165

Median for Colorectal Surgery (Proctology): 106

Drug cost

$3,993

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

9.1%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mesalamine Generic 11 $2,663
Loperamide Loperamide Hcl Brand 15 $689
Neomycin Sulfate Generic 62 $316
Metronidazole Generic 66 $169
Hydrocortisone Generic 11 $156

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$314,903

Medicare's payments for the services billed

Medicare patients

434

Average age 74

Services billed

1,307

241 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 36%
Ischemic heart disease 34%
Diabetes 29%
Osteoporosis 20%
Chronic kidney disease 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record